Types of Research
- (-) Remove East Africa Region and Selected Countries filter East Africa Region and Selected Countries
- (-) Remove Global filter Global
- (-) Remove South Asia Region and Selected Countries filter South Asia Region and Selected Countries
- (-) Remove Market & Value Chain Analysis filter Market & Value Chain Analysis
- (-) Remove Research & Development filter Research & Development
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.
According to AGRA's 2017 Africa Agriculture Status Report, smallholder farmers make up to about 70% of the population in Africa. The report finds that 500 million smallholder farms around the world provide livelihoods for more than 2 billion people and produce about 80% of the food in sub-Saharan Africa and Asia. Many development interventions and policies therefore target smallholder farm households with the goals of increasing their productivity and promoting agricultural transformation. Of particular interest for agricultural transformation is the degree to which smallholder farm households are commercializating their agricultural outputs, and diversifying their income sources away from agriculture. In this project, EPAR uses data from the World Bank's Living Standards Measurement Study - Integrated Surveys on Agriculture (LSMS-ISA) to analyze and compare characteristics of smallholder farm households at different levels of crop commercialization and reliance on farm income, and to evaluate implications of using different criteria for defining "smallholder" households for conclusions on trends in agricultural transformation for those households.
An ongoing stream of EPAR research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. For this project, we seek to summarize the key public good characteristics of R&D investment for agriculture in general and for different subsets of crops, and hypothesize how these characteristics might be expected to affect public, private, or philanthropic funders’ investment decisions.
This research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. We summarize the public good characteristics of R&D for agriculture in general and for commodity and subsistence crops in particular, as well as R&D for health in general and for neglected diseases in particular, with a focus on Sub-Saharan Africa and South Asia. Finally, we present rationales for which funders are predicted to fund which R&D types based on these funder and R&D characteristics. We then compile available statistics on funding for agricultural and health R&D from private, public and philanthropic sources, and compare trends in funding from these sources against expectations. We find private agricultural R&D spending focuses on commodity crops (as expected). However contrary to expectations we find public and philanthropic spending also goes largely towards these same crops rather than staples not targeted by private funds. For health R&D private funders similarly concentrate on diseases with higher potential financial returns. However unlike in agricultural R&D, in health R&D we observe some specialization across funders – especially for neglected diseases R&D - consistent with funders’ expected relative advantages.
Cereal yield variability is influenced by initial conditions such as suitability of the farming system for cereal cultivation, current production quantities and yields, and zone-specific potential yields limited by water availability. However, exogenous factors such as national policies, climate, and international market conditions also impact farm-level yields directly or provide incentives or disincentives for farmers to intensify production. We conduct a selective literature review of policy-related drivers of maize yields in Ethiopia, Kenya, Malawi, Rwanda, Tanzania, and Uganda and pair the findings with FAOSTAT data on yield and productivity. This report presents our cumulative findings along with contextual evidence of the hypothesized drivers behind maize yield trends over the past 20 years for the focus countries.
The review consists of a summary of the emergence of agribusiness clusters, SEZs and incubators since 1965 (with a focus on smallholder agriculture-based economies in Latin America, Africa, and Asia), followed by a series of brief case studies of example programs with particular relevance for guiding proposed clusters/incubators in the countries of Ethiopia, Tanzania, Nigeria and the Eastern Indian states of Uttar Pradesh, Bihar, and Odisha. Summary conclusions draw upon published reports and primary analysis of case studies to highlight apparent determinants of success and failure in agribusiness investment clusters and incubators, including characteristics of the business environment (markets, policies) and characteristics of the organizational structure (clusters, accelerators) associated with positive smallholder outcomes.
The purpose of this analysis is to provide a measure of marketable surplus of maize in Tanzania. We proxy marketable surplus with national-level estimates of total maize sold, presumably the surplus for maize producing and consuming households. We also provide national level estimates of total maize produced and estimate “average prices” for Tanzania which allows this quantity to be expressed as an estimate of the value of marketable surplus. The analysis uses the Tanzanian National Panel Survey (TNPS) LSMS – ISA which is a nationally representative panel survey, for the years 2008/2009 and 2010/2011. A spreadsheet provides our estimates for different subsets of the sample and using different approaches to data cleaning and weighting. The total number of households for Tanzania was estimated with linear extrapolation based on the Tanzanian National Bureau of Statistics for the years 2002 and 2012. The weighted proportions of maize-producing and maize-selling households were multiplied to the national estimate of total households. This estimate of total Tanzanian maize-selling and maize-producing households was then multiplied by the average amount sold and by the average amount produced respectively to obtain national level estimates of total maize sold and total maize produced in 2009 and 2011.
In this brief we analyze patterns of intercropping and differences between intercropped and monocropped plots among smallholder farmers in Tanzania using data from the 2008/2009 wave of the Tanzania National Panel Survey (TZNPS), part of the Living Standards Measurement Study – Integrated Surveys on Agriculture (LSMS-ISA). Intercropping is a planting strategy in which farmers cultivate at least two crops simultaneously on the same plot of land. In this brief we define intercropped plots as those for which respondents answered “yes” to the question “Was cultivation intercropped?” We define “intercropping households” as those households that intercropped at least one plot at any point during the year in comparison to households that did not intercrop any plots. The analysis reveals few significant, consistent productivity benefits to intercropping as currently practiced. Intercropped plots are not systematically more productive (in terms of value produced) than monocropped plots. The most commonly cited reason for intercropping was to provide a substitute crop in the case of crop failure. This suggests that food and income security are primary concerns for smallholder farmers in Tanzania. A separate appendix includes the details for our analyses.